PK and Safety of BR1015-A (Fimasartan/Indapamide) in Healthy Volunteers

Phase 1, randomised, open-label trial of fimasartan and indapamide in hypertension (HTN) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve from time 0 to t of Fimasartan at 48 hours, Area Under the Curve from time 0 to t of Indapamide at 72 hours and 2 more. Planned start Apr 2026; status: not yet recruiting.